trending Market Intelligence /marketintelligence/en/news-insights/trending/9Si2M1sOUxpYTuoDoiFO8g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Exicure moves to Nasdaq Capital Market, prices $55M public offering

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Exicure moves to Nasdaq Capital Market, prices $55M public offering

Exicure Inc., a pharmaceutical company specializing in gene regulatory and immunotherapeutic drugs, has uplisted to the Nasdaq Capital Market.

The Skokie, Ill.-based company began trading under the symbol XCUR on July 31.

Exicure also priced a previously announced underwritten public offering of 27,500,000 shares at $2 apiece, with a goal of raising $55 million. The underwriters of the offer have a 30-day option to buy an additional 4,125,000 common shares. The offering is set to close on Aug. 2.

Proceeds from the offering will be used to advance immuno-oncology therapy AST-008 in a phase 1b/2 clinical trial and to develop a Spherical Nucleic Acid, or SNA, therapeutic candidate in a neurology condition. Remaining proceeds will be used for general corporate purposes.

Guggenheim Securities is sole book-running manager for the offering, while Chardan is acting as lead manager. H.C. Wainwright & Co. and Ladenburg Thalmann are co-managers for the offering.